Why a DCF Doesn't Fit Ventas, Inc. (VTR)
REIT - Healthcare Facilities · NYSE
A cash-flow DCF is not the right model for VTR
Ventas, Inc. is a bank, insurer, or real estate company. A standard discounted cash flow model values a business on its free cash flow, but for these companies free cash flow is not a clean measure of value. Banks and insurers are valued on book value, return on equity, and a price-to-earnings multiple; REITs are valued on funds from operations (FFO) and dividends, not free cash flow. Running a free cash flow DCF here would produce a misleading number, so none is shown.
Current Price
$97.72
COMPETITIVE MOAT
↑Senior Housing Demand Tailwinds
Ventas benefits from strong macro tailwinds in senior housing demand. This demographic shift creates a sustained need for its healthcare facilities.
↑Diversified Healthcare Portfolio
The company's portfolio spans senior housing, medical office buildings, and other healthcare properties. This diversification reduces reliance on any single segment.
↑Established Tenant Relationships
Ventas has built long-term relationships with healthcare operators. These established partnerships provide a degree of stability and recurring revenue.
INVESTMENT RISKS
↓High Debt Levels
Ventas carries a substantial amount of debt. Rising interest rates or a downturn in its operating performance could strain its ability to service this debt.
↓Regulatory and Reimbursement Changes
Changes in healthcare regulations or reimbursement policies could negatively impact the profitability of its tenants and, consequently, Ventas.
↓Interest Rate Sensitivity
As a REIT, Ventas's profitability is sensitive to interest rate fluctuations. Higher rates can increase borrowing costs and potentially reduce property valuations.
Company Overview
As an S&P 500 company, Ventas operates strategically at the nexus of the dynamic healthcare and real estate industries. We stand as one of the world's foremost Real Estate Investment Trusts (REITs), utilizing financial capital to unlock property value. Our partnerships extend to leading care providers, developers, research and medical institutions, innovators, and healthcare organizations, all of whom benefit from the significant demographic trend of an aging population. For over two decades, Ventas has pursued a steadfast and effective strategy: maintaining a high-quality, diverse portfolio of assets and varied capital streams to skillfully navigate market fluctuations. A dedicated and experienced team collaborates with industry-leading partners to generate consistent, increasing cash flows and superior returns on a strong balance sheet, ultimately enriching Ventas's shareholders. As of September 30, 2020, Ventas either owned outright or managed through unconsolidated joint ventures approximately 1,200 properties.
Frequently Asked Questions
Why isn't a discounted cash flow model right for valuing Ventas, Inc.?
As a REIT, Ventas, Inc. must pay out most of its income as dividends and carries heavy non-cash depreciation on its buildings, so reported net income and free cash flow understate how much the properties actually earn. A DCF built on those figures misses the real cash the portfolio produces. A REIT is read on funds from operations and dividends instead.
How is Ventas, Inc. (VTR) valued instead?
Ventas, Inc. is better read through price-to-FFO, which uses funds from operations, and the dividend yield rather than price-to-earnings, together with occupancy and the quality of its properties. The VTR PE view is a starting point, but multiples based on funds from operations fit a REIT better.
Learn More
- See VTR PE Valuation → — The earnings-based method that fits this kind of business
- PE Methodology — Guide to PE ratio stock valuation
- P/E Ratio — How an earnings multiple values a stock
- Price-to-Book — A core metric for valuing banks and insurers
- Return on Equity — Why ROE drives bank and insurer valuations
Related Valuations
All Real Estate valuationsDCF and P/E value VTR with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-07-29. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.